Skip to main content
    A

    Akari Therapeutics PLC (AKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.19
    -0.61 (-8.97%)

    Market Cap: $15.54M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Akari Therapeutics PLC (AKTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Akari Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$17.30M, operating cash flow was -$10.57M and free cash flow was -$10.57M. The quarter ended Sep 30, 2026 had net income of -$4.84M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $17.27M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Cost of revenueN/A$14.00K$4.00K$3.71K$4.13K$8.91K$19.20K$35.85K$0$39.77K
    Gross profitN/A-$14.00K-$4.00K-$3.71K-$4.13K-$8.91K-$19.20K-$35.85K$0-$39.77K
    Research and development$2.81M$6.98M$8.02M$9.56M$9.13M$12.19M$16.65M$15.59M$23.29M$17.31M
    Operating income-$17.27M-$21.64M-$16.81M-$23.09M-$17.21M-$17.98M-$24.87M-$19.99M-$34.96M-$27.25M
    Net income-$17.30M-$19.79M-$10.01M-$17.75M-$17.42M-$17.08M-$16.85M-$19.95M-$27.92M-$18.14M
    EBITDAN/A-$19.53M-$10.00M-$17.74MN/A-$17.97M-$24.73M-$16.43MN/A-$27.21M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    RevenueN/A$0$0$0$0$0$26.00K$0$0$0$0$0
    Gross profitN/AN/AN/AN/AN/AN/A-$1.00KN/AN/AN/A-$13.00KN/A
    Operating income-$4.68M-$4.60M-$15.76M-$3.23M-$7.40M-$3.12M-$3.52M-$4.29M-$2.93M-$7.45M-$5.99M-$5.09M
    Net income-$4.84M-$4.81M-$14.46M-$5.30M-$6.40M-$1.90M-$3.71M-$3.77M-$2.90M-$7.56M-$5.57M-$4.14M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $754.00K by $4.45M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$47.89M$50.56M$4.36M$13.83M$11.65M$14.60M$10.31M$16.45M$29.05M$45.87M
    Current assets$5.46M$2.95M$4.34M$13.81M$11.63M$14.58M$10.27M$16.40M$28.81M$45.63M
    Cash and equivalents$5.20M$2.60M$3.85M$13.25M$9.36M$14.06M$5.73M$5.97M$28.11M$34.10M
    Total liabilities$19.56M$28.33M$4.58M$12.04M$6.09M$5.22M$6.47M$3.08M$9.07M$11.77M
    Short-term debt$754.00K$3.26MN/AN/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$28.33M$22.23M-$229.00K$1.79M$5.55M$9.38M$3.84M$13.38M$19.98M$34.10M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$36.58M$38.62M$33.89M$47.89M$45.38M$50.91M$50.96M$50.56M$2.73M$5.08M$2.77M$4.36M
    Total liabilities$19.08M$20.03M$19.51M$19.56M$22.69M$25.31M$29.21M$28.33M$9.43M$8.78M$6.33M$4.58M
    Cash and equivalents$5.74M$7.69M$2.77M$5.20M$2.48M$2.71M$2.58M$2.60M$2.25M$4.18M$1.31M$3.85M
    Shareholder equity$17.50M$18.59M$14.38M$28.33M$22.69M$25.61M$21.75M$22.23M-$6.69M-$3.70M-$3.55M-$229.00K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$10.57M-$12.55M-$16.43M-$21.50M-$18.85M-$16.95M-$12.92M-$22.54M-$31.60M-$24.62M
    Capital expenditures$0$0$0$0$0$0$0$36.88K$36.88K$54.75K
    Free cash flow-$10.57M-$12.55M-$16.43M-$21.50M-$18.85M-$16.95M-$12.92M-$22.57M-$31.64M-$24.68M
    Investing cash flowN/A$382.00KN/AN/AN/AN/AN/A$9.99M$9.99M-$10.07M
    Financing cash flow$13.17M$10.99M$7.02M$25.29M$14.29M$25.07M$12.65M$306.00K$15.67M$15.67M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.22M-$3.11M-$2.49M-$3.04M-$2.10M-$3.26M-$2.15M-$2.12M-$1.49M-$4.89M-$4.04M-$4.41M
    Free cash flow-$4.22M-$3.11M-$2.49M-$3.04MN/A-$3.26M-$2.15M-$2.12M-$1.49M-$4.89M-$4.04M-$4.41M
    Last 12 quarters

    Frequently Asked Questions About AKTX

    What is Akari Therapeutics' annual revenue?

    Akari Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Akari Therapeutics profitable?

    No. Akari Therapeutics reported net income of -$17.30M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does AKTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.57M minus capital expenditures of $0 produced free cash flow of -$10.57M.

    How much debt does Akari Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $754.00K and cash and equivalents of $5.20M.